2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1209R
    Etofylline (Standard)
    		Inhibitor
    Etofylline (Standard) is the analytical standard of Etofylline. This product is intended for research and analytical applications. Etofylline (7-(β-Hydroxyethyl)theophylline) is a N-7-substituted derivative of Theophylline. Etofylline is a bronchodilator which can be used for the research of asthma. Etofylline is also an anticholesteremic and reduces total cholesterol level in the blood.
    Etofylline (Standard)
  • HY-N0579R
    Fraxin (Standard)
    		Inhibitor
    Fraxin (Standard) is the analytical standard of Fraxin. This product is intended for research and analytical applications. Fraxin isolated from Cortex Fraxini, is a glucoside of fraxetin and reported to exert potent anti-oxidative stress action, anti-inflammatory and antimetastatic properties. Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme.
    Fraxin (Standard)
  • HY-139096
    4-Pentadecylbenzylphosphonic acid
    		Inhibitor
    4-Pentadecylbenzylphosphonic acid is an Autotaxin (ATX) inhibitor. 4-Pentadecylbenzylphosphonic acid has antitumor activity.
    4-Pentadecylbenzylphosphonic acid
  • HY-119799
    UK-500001
    		Inhibitor
    UK-500001 is an orally active inhibitor for phosphodiesterase 4 (PDE4), which inhibits PDE4D3 (IC50 is 0.28 nM), PDE4B2 (IC50 is 22.8 nM), PDE4A4 (IC50 is 26.1 nM) and PDE4C2 (IC50 is 271 nM). UK-500001 exhibits anti-inflammatory efficacy and inhibits TNF-α and IFN-γ release in human and rodent macrophagic cell lines in nanomolar levels. UK-500001 ameliorates chronic obstructive pulmonary disease (COPD) and asthma.
    UK-500001
  • HY-149716
    MEY-003
    MEY-003 is an Autotaxin(ATX) inhibitor with EC50s of 460 nM and 1.09 μM for hATX-β and hATX-ɣ (analysis with LPC18:1). MEY-003 behaves as a non-competitive inhibitor with K iof 432 nM. MEY-003 can be used for targeted ATX-related disease research .
    MEY-003
  • HY-B0715S3
    Pentoxifylline-d3
    		Inhibitor
    Pentoxifylline-d3 (BL-191-d3) is deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.
    Pentoxifylline-d<sub>3</sub>
  • HY-155165
    Dazonone
    		Inhibitor
    Dazonone is a phosphodiesterase III inhibitor with the IC50 of 1.68 μM.
    Dazonone
  • HY-B0764R
    Bucladesine (sodium) (Standard)
    		Inhibitor
    Bucladesine (sodium) (Standard) is the analytical standard of Bucladesine (sodium). This product is intended for research and analytical applications. Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing.
    Bucladesine (sodium) (Standard)
  • HY-W715511
    N-Desethyl-N-methyl vardenafil
    		Inhibitor
    N-Desethyl-N-methyl vardenafil (Demethyl-vardenafil), an analog of Vardenafil (HY-B0442), is a PDE5 inhibitor with an IC50 value of 0.14 μM.
    N-Desethyl-N-methyl vardenafil
  • HY-141555
    5,5′-(1,3-Propanediyl)bis-1,3,4-oxadiazole-2(3H)-thione
    		Inhibitor
    5,5′-(1,3-Propanediyl)bis-1,3,4-oxadiazole-2(3H)-thione is a weak inhibitor for snake venom and human recombinant phosphodiesterase 1 with IC50 of 429 and 467 μM. 5,5′-(1,3-Propanediyl)bis-1,3,4-oxadiazole-2(3H)-thione inhibits mushroom tyrosinase weakly, with Ki of 1.9 μM.
    5,5′-(1,3-Propanediyl)bis-1,3,4-oxadiazole-2(3H)-thione
  • HY-12085S1
    Apremilast-d8
    		Inhibitor
    Apremilast-d8 (CC-10004-d8) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM.
    Apremilast-d<sub>8</sub>
  • HY-136520B
    Xanthoanthrafil
    		Inhibitor
    Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC50 of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction.
    Xanthoanthrafil
  • HY-100927R
    Ro 20-1724 (Standard)
    		Inhibitor
    Ro 20-1724 (Standard) is the analytical standard of Ro 20-1724. This product is intended for research and analytical applications. Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase (PDE4/PDE IV) with a Ki of 1930 nM. Neuroprotective effect.
    Ro 20-1724 (Standard)
  • HY-131101R
    Nor-Acetildenafil (Standard)
    Nor-Acetildenafil (Standard) is the analytical standard of Nor-Acetildenafil. This product is intended for research and analytical applications. Nor-Acetildenafil is an Acetildenafil derivative. Acetildenafil is a synthetic agent which acts as a phosphodiesterase inhibitor.
    Nor-Acetildenafil (Standard)
  • HY-W838042
    Hedgehog IN-8
    		Inhibitor
    Hedgehog IN-8 effectively inhibits hedgehog signaling and phosphodiesterase activity.
    Hedgehog IN-8
  • HY-116262
    SCH 51866
    		Inhibitor
    SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC50=70 nM) and PDE5 (IC50=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC50=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension.
    SCH 51866
  • HY-N2168R
    Pinoresinol 4-O-β-D-glucopyranoside (Standard)
    		Inhibitor
    Pinoresinol 4-O-β-D-glucopyranoside (Standard) is the analytical standard of Pinoresinol 4-O-β-D-glucopyranoside (HY-N2168). This product is intended for research and analytical applications. Pinoresinol 4-O-β-D-glucopyranoside is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects.
    Pinoresinol 4-O-β-D-glucopyranoside (Standard)
  • HY-172297
    Pyrazole N-Desmethyl sildenafil
    		Inhibitor
    Pyrazole N-Desmethyl sildenafil (Compound 10) is an analog of Sildenafil (HY-15025). Pyrazole N-Desmethyl sildenafil shows 16% inhibition on Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) with 100 µM.
    Pyrazole N-Desmethyl sildenafil
  • HY-119316A
    CM-545
    		Inhibitor
    (cis)-CM-414, the cis-isomer of CM-414, is a dual inhibitor of PDE5, HDAC1, HDAC2, HDAC3, and HDAC6 with pIC50 values of 7.47, 6.65, 6.14, 6.55, and 6.84, repectively.
    CM-545
  • HY-106996
    AWD 12-281
    		Inhibitor
    AWD 12-281 is an orally active and highly selective phosphodiesterase 4 (PDE4) inhibitor (IC50 = 9.7 nM). AWD 12-281 is used in the study of allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
    AWD 12-281
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.